Table 1.
Patient characteristics
| Variables | No. of patients (%) |
|---|---|
| Gender |
|
| Male |
74 (80.4) |
| Female |
18 (19.6) |
| Age (years) |
|
| Median |
61 |
| Range |
42–86 |
| ECOG performance score |
|
| 0–1 |
89 (96.7) |
| 2 |
3 (3.3) |
| Child-Pugh class |
|
| A |
68 (73.9) |
| B |
24 (26.1) |
| Viral etiology |
|
| HBs-Ag (+) |
69 (75.0) |
| HBs-Ag (-) |
23 (25.0) |
| Tumor volume (cm3) |
|
| Median |
8.6 |
| Range |
0.6–125.3 |
| Previous treatments |
|
| None |
1 (1.1) |
| TACE |
47 (51.1) |
| TACE, RFA |
21 (22.8) |
| TACE, PEIT |
4 (4.3) |
| TACE, RFA, PEIT |
2 (2.2) |
| Resection |
1 (1.1) |
| Resection, TACE |
11 (11.9) |
| Resection, TACE, RFA |
2 (2.2) |
| Resection, TACE, PEIT |
1 (1.1) |
| RFA | 2 (2.2) |
Abbreviations:ECOG Eastern Cooperative Oncology Group, HBs-Ag hepatitis B surface-antigen, TACE transarterial chemoembolization, RFA radiofrequency ablation, PEIT percutaneous ethanol injection treatment.